SINCE PUBLICATION of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) in the November 24, 1997, issue of the ARCHIVES,1 several long-term morbidity and mortality trials and several comparative medication studies have been published. It is of interest to review the rationale for the JNC VI recommendations and discuss possible revisions that may be indicated on the basis of data from these new trials.
Moser M. National Recommendations for the Pharmacological Treatment of HypertensionShould They Be Revised?. Arch Intern Med. 1999;159(13):1403-1406. doi:10.1001/archinte.159.13.1403